Category - Developments

Developments

Rigel Pharma enrolls first patient in Phase 3 autoimmune hemolytic anemia trial

Rigel Pharmaceuticals (NASDAQ:RIGL) enrolled the first patient in its pivotal Phase 3 trial of fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia (AIHA).

May 16, 2019

Developments

Ceapro receives site license from Health Canada

Ceapro’s (TSXV:CZO) two bioprocessing plants in Alberta received a site license from the Health Canada Natural and Non-Prescription Health Products Directorate, which enables the company to fabricate, package, label...

May 15, 2019

Developments

Principia Biopharma doses first patient in Phase 2b MS trial

Principia Biopharma (NASDAQ:PRNB) has dosed the first patient in its Phase 2b clinical trial of SAR442168 in patients with relapsing multiple sclerosis (MS). Neuroinflammation and an increase in the number of B cells in...

May 15, 2019

Developments

Athersys gets FDA fast track designation for acute respiratory distress syndrome

Athersys’ (NASDAQ:ATHX) MultiStem cell therapy for the treatment of acute respiratory distress syndrome (ARDS) has received FDA fast track designation. ARDS is a widespread inflammation of the lungs that can be...

May 15, 2019

Developments

MeiraGTx reports positive topline data from Phase 1/2 retinal dystrophy trial

MeiraGTx (NASDAQ:MGTX) reported that AAV-RPE65, its investigational gene therapy for the treatment of retinal dystrophy, met the primary endpoint of safety and tolerability in a Phase 1/2 study, as well as demonstrated...

May 14, 2019

Developments

Homology’s PKU gene therapy gets FDA fast track designation

Homology Medicines’ (NASDAQ:FIXX) received FDA fast track designation for HMI-102, a gene therapy for the treatment of adults with phenylketonuria (PKU), a rare genetic disease affecting metabolism. Individuals with PKU...

May 14, 2019

Developments

Cyclerion completes enrollment for Phase 2 studies of praliciguat

Cyclerion Therapeutics (NASDAQ:CYCN) has completed enrollment for Phase 2 studies testing praliciguat in diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF). Praliciguat stimulates soluble...

May 14, 2019

Developments

PharmaCyte Biotech develops cannabinoid-activating cell line for cancer treatment

PharmaCyte Biotech (OTCQB:PMCB) and its research partner, the University of Northern Colorado, have developed a cannabinoid-activating human cell line for use in its live-cell encapsulation technology for the treatment...

May 13, 2019

Developments

Titan Pharma in pact with Express Scripts’ Accredo to further expand patient access to Probuphine

Titan Pharmaceuticals (NASDAQ:TTNP) signed a product purchase and supply agreement with Accredo specialty pharmacy, a subsidiary of Express Scripts, further expanding patient access to its Probuphine implant for the...

May 13, 2019

Developments

Magenta Therapeutics reports initial Phase 2 data for stem cell therapy

Magenta Therapeutics (NASDAQ:MGTA) reported preliminary data from its Phase 2 trial testing MGTA-456, a hematopoietic stem cell (HSC) therapy, in patients with inherited metabolic disorders. The Phase 2 study is...

May 10, 2019

Category - Developments

Rigel Pharma enrolls first patient in Phase 3 autoimmune hemolytic anemia trial

Ceapro receives site license from Health Canada

Principia Biopharma doses first patient in Phase 2b MS trial

Athersys gets FDA fast track designation for acute respiratory distress syndrome

MeiraGTx reports positive topline data from Phase 1/2 retinal dystrophy trial

Homology’s PKU gene therapy gets FDA fast track designation

Cyclerion completes enrollment for Phase 2 studies of praliciguat

PharmaCyte Biotech develops cannabinoid-activating cell line for cancer treatment

Titan Pharma in pact with Express Scripts’ Accredo to further expand patient access to Probuphine

Magenta Therapeutics reports initial Phase 2 data for stem cell therapy

General

More